Trial Profile
A Phase 2 Open Label Study of Oral Lorlatinib in Patients With Relapsed ALK Positive Lymphoma Previously Treated With ALK Inhibitors (CRU3)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 23 Jan 2024
Price :
$35
*
At a glance
- Drugs Lorlatinib (Primary)
- Indications Anaplastic large cell lymphoma; Lymphoma
- Focus Therapeutic Use
- Acronyms CRU3
- 12 Dec 2023 Preliminary Results presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 04 Aug 2023 Planned End Date changed from 1 Dec 2022 to 1 Dec 2024.
- 04 Aug 2023 Planned primary completion date changed from 1 Dec 2022 to 1 Dec 2024.